MetaCap

Genelux (GNLX) vs Organogenesis (ORGO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genelux (GNLX) has outperformed Organogenesis (ORGO) over the past year, losing 56.3% versus a loss of 86.2%. Genelux is the larger company by market cap ($103.4 million vs $100.2 million), about 1.0 times the size, while Organogenesis is growing revenue faster (+17.0% vs +0.0%). Organogenesis converts more of its revenue into profit, with a net margin of 6.6% versus -401812.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GNLX-56.25%ORGO-86.20%
+18%-37%-91%
Nov 21, 20251 yearNov 20, 2026
GNLX-63.89%ORGO-70.32%
+510%+206%-99%
Jan 23, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GNLX versus ORGO key metrics
MetricGNLXORGO
Share price$2.17$0.7716
Market cap$103.36M$100.16M
1-day change-4.82%-2.23%
YTD return-50.23%-85.10%
1-year return-56.25%-86.20%
5-year return—-92.25%
EPS (TTM)$-0.88$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.00K$564.17M
Revenue growth (YoY)0.00%+17.04%
Net income (latest FY)$-32.15M$37.03M
Operating margin-415175.00%7.92%
Net margin-401812.50%6.56%
52-week high$5.89$5.91
52-week low$1.77$0.73
Distance from 52-week high-63.16%-86.93%
Analyst consensusstrong_buyhold
Avg. price target upside+767.74%—
Average volume333.31K850.26K
Shares outstanding47.63M129.80M
Employees25854
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GNLX has outperformed ORGO by 29.9 percentage points over the past year.
  • Organogenesis is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
  • Organogenesis grew revenue faster in its latest fiscal year (+17.04% vs 0.00%).

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

About Organogenesis

ORGO stock →

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.

Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees

GNLX vs ORGO FAQ

Which is bigger, Genelux or Organogenesis?

Genelux (GNLX) is larger, with a market capitalization of $103.36M compared with $100.16M for Organogenesis (ORGO).

Which stock has performed better over the past year, GNLX or ORGO?

GNLX returned -56.25% over the past 12 months, compared with -86.20% for ORGO (price return, excluding dividends). Past performance does not predict future results.

Are Genelux and Organogenesis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons